家庭移动指导心脏康复作为欧洲老年患者拒绝门诊心脏康复替代策略的有效性:随机临床试验
本研究为平行多中心随机临床试验,纳入179例近期诊断为急性冠脉综合征、冠脉血运重建、瓣膜病手术或介入治疗或确诊冠心病且拒绝参加门诊心脏康复的老年患者(中位年龄72岁)。干预组接受6个月基于远程监测和动机性访谈指导的家庭心脏康复,对照组不接受任何形式心脏康复。结果显示干预组6个月和12个月峰值摄氧量均改善,且组间差异显著,不良事件发生率低且两组无差异。
要点
- 6个月家庭移动指导心脏康复可改善老年冠心病或瓣膜干预后患者的峰值摄氧量。
- 干预组6个月峰值摄氧量改善1.6 mL/kg/min,12个月改善1.2 mL/kg/min。
- 不良事件发生率低且两组无差异,提示家庭康复方案安全。
核心结论
- 对于65岁及以上冠心病或瓣膜干预后拒绝门诊心脏康复的患者,6个月家庭移动指导心脏康复安全且能改善峰值摄氧量。
研究设计与样本
- 平行多中心随机临床试验,2015年11月11日至2018年1月3日纳入,随访至2019年1月17日,涉及5个欧洲国家6个心脏机构。
- 共识别4236例近期诊断为急性冠脉综合征、冠脉血运重建、瓣膜病手术或介入治疗或确诊冠心病患者,其中996例拒绝开始心脏康复。
- 179例符合纳入和排除标准并同意参与,随机分为家庭移动指导心脏康复组(n=89)和对照组(n=90),159例(89%)符合主要终点分析,151例(84%)完成1年随访。
主要发现
- 干预组6个月和12个月峰值摄氧量分别改善1.6(95%CI 0.9-2.4)mL/kg/min和1.2(95%CI 0.4-2.0)mL/kg/min。
- 对照组6个月和12个月峰值摄氧量分别变化+0.2(95%CI -0.4至0.8)mL/kg/min和+0.1(95%CI -0.5至0.7)mL/kg/min。
- 6个月和12个月时干预组峰值摄氧量变化均大于对照组,组间差异分别为+1.2(95%CI 0.2-2.1)mL/kg/min和+0.9(95%CI 0.05-1.8)mL/kg/min。
- 不良事件发生率低且干预组与对照组无差异。
临床怎么用
- 对于拒绝参加门诊心脏康复的老年冠心病或瓣膜干预后患者,可考虑提供6个月家庭移动指导心脏康复作为替代策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although nonparticipation in cardiac rehabilitation is known to increase cardiovascular mortality and hospital readmissions, more than half of patients with coronary artery disease in Europe are not participating in cardiac rehabilitation. OBJECTIVE: To assess whether a 6-month guided mobile cardiac rehabilitation (MCR) program is an effective therapy for elderly patients who decline participation in cardiac rehabilitation. DESIGN, SETTING, AND PARTICIPANTS: Patients were enrolled in this parallel multicenter randomized clinical trial from November 11, 2015, to January 3, 2018, and follow-up was completed on January 17, 2019, in a secondary care system with 6 cardiac institutions across 5 European countries. Researchers assessing primary outcome were masked for group assignment. A total of 4236 patients were identified with a recent diagnosis of acute coronary syndrome, coronary revascularization, or surgical or percutaneous treatment for valvular disease, or documented coronary artery disease, of whom 996 declined to start cardiac rehabilitation. Subsequently, 179 patients who met the inclusion and exclusion criteria consented to participate in the European Study on Effectiveness and Sustainability of Current Cardiac Rehabilitation Programmes in the Elderly trial. Data were analyzed from January 21 to October 11, 2019. INTERVENTIONS: Six months of home-based cardiac rehabilitation with telemonitoring and coaching based on motivational interviewing was used to stimulate patients to reach exercise goals. Control patients did not receive any form of cardiac rehabilitation throughout the study period. MAIN OUTCOMES AND MEASURES: The primary outcome parameter was peak oxygen uptake (Vo2peak) after 6 months. RESULTS: Among 179 patients randomized (145 male [81%]; median age, 72 [range, 65-87] years), 159 (89%) were eligible for primary end point analysis. Follow-up at 1 year was completed for 151 patients (84%). Peak oxygen uptake improved in the MCR group (n = 89) at 6 and 12 months (1.6 [95% CI, 0.9-2.4] mL/kg-1/min-1 and 1.2 [95% CI, 0.4-2.0] mL/kg-1/min-1, respectively), whereas there was no improvement in the control group (n = 90) (+0.2 [95% CI, -0.4 to 0.8] mL/kg-1/min-1 and +0.1 [95% CI, -0.5 to 0.7] mL/kg-1/min-1, respectively). Changes in Vo2peak were greater in the MCR vs control groups at 6 months (+1.2 [95% CI, 0.2 to 2.1] mL/kg-1/min-1) and 12 months (+0.9 [95% CI, 0.05 to 1.8] mL/kg-1/min-1). The incidence of adverse events was low and did not differ between the MCR and control groups. CONCLUSIONS AND RELEVANCE: These results suggest that a 6-month home-based MCR program for patients 65 years or older with coronary artery disease or a valvular intervention was safe and beneficial in improving Vo2peak when compared with no cardiac rehabilitation. TRIAL REGISTRATION: trialregister.nl Identifier: NL5168.
引用
- Snoek JA, Prescott EI, van der Velde AE, et al. Effectiveness of Home-Based Mobile Guided Cardiac Rehabilitation as Alternative Strategy for Nonparticipation in Clinic-Based Cardiac Rehabilitation Among Elderly Patients in Europe: A Randomized Clinical Trial. JAMA Cardiol. 2021. PMID: 33112363. doi:10.1001/jamacardio.2020.5218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。